Comparison of Bioavailability of Liposomal and Traditional Formulation of Vitamin C

Sponsor
AronPharma Sp. z o. o. (Industry)
Overall Status
Completed
CT.gov ID
NCT05843617
Collaborator
Medical University of Warsaw (Other), Medical University of Gdańsk (Other)
10
1
2
3.3
3

Study Details

Study Description

Brief Summary

The aim of the study was to compare the profiles of vitamin C serum concentration in healthy volunteers after the single oral administration either in a liposomal (Liposovit-C pure) or traditional formulation.

Condition or Disease Intervention/Treatment Phase
  • Dietary Supplement: Liposomal Vitamin C (Liposovit-C)
  • Dietary Supplement: Traditional Vitamin C
N/A

Detailed Description

The randomized, double-blind, cross-over study was conducted under the supervision of physician on a group of 10 healthy subjects. The volunteers received 1g of vitamin C in a traditional formulation (powder in capsules), and after 14 days of a washout period 1 gram of Liposovit-C pure (liposomal formulation, powder in capsules). Venous blood was collected from each participant of the study immediately before the administration of a studied substance and 30 minutes, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 24 hours post the administration.

Study Design

Study Type:
Interventional
Actual Enrollment :
10 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Masking:
Double (Participant, Investigator)
Primary Purpose:
Other
Official Title:
Comparison of Bioavailability of Liposomal and Traditional Formulation of Vitamin C
Actual Study Start Date :
Feb 28, 2022
Actual Primary Completion Date :
Jun 9, 2022
Actual Study Completion Date :
Jun 9, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: Liposomal Vitamin C (Liposovit-C)

Single oral dose of liposomal vitamin C formulation

Dietary Supplement: Liposomal Vitamin C (Liposovit-C)
1000 mg of ascorbic acid in liposomal formulation

Active Comparator: Traditional Vitamin C

Single oral dose of traditional vitamin C formulation

Dietary Supplement: Traditional Vitamin C
1000 mg of ascorbic acid in traditional formulation

Outcome Measures

Primary Outcome Measures

  1. Total amount of ascorbic acid that has been absorbed, defined as AUC [baseline, 30 minutes, 1, 2, 3, 4, 6, 8, 10, 24 hours post the administration]

    Comparison of the bioavailability of formulations based on the total amount of ascorbic acid that has been absorbed, defined as AUC (area under the curve)

  2. Maximum concentration of ascorbic acid (Cmax) [baseline, 30 minutes, 1, 2, 3, 4, 6, 8, 10, 24 hours post the administration]

    Maximum concentration of ascorbic acid achieved in the blood after administration of both formulations

Secondary Outcome Measures

  1. Concentration of ascorbic acid after 24 hours (C24h) [24 hours post the administration]

    Comparison of the concentration achieved in the blood after 24 hours (C24h) from the administration of both formulations

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 65 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Women and men, 18-65 years old.

  • Signed informed consent.

  • No injuries or hospitalizations within the last 3 months.

  • Refraining from consuming any vitamin C supplements or foods enriched with vitamin C for a period of 72 hours. Limiting excessive consumption of red peppers, parsley (stalks), Brussels sprouts, broccoli, turnip, tomatoes, cabbage, spinach, watercress, citrus fruits, and citrus juices. Not taking acetylsalicylic acid (aspirin, polopiryna, etopiryna) during the study.

  • Participants should fast for at least 8-12 hours prior to the administration of the preparations.

Exclusion Criteria:
  • Unwilling to give consent.

  • Injuries within the last 3 months.

  • Cancer (current or past).

  • Renal dysfunction (eGFR < 60 ml/min).

  • Gastrointestinal disorders (including use of antacids).

  • Tobacco use in any form.

  • Pregnancy/breastfeeding.

  • Patient after organ transplantation, after a stroke, use of anticoagulants, use of immunosuppressants.

  • Female patient receiving hormonal therapy (contraception).

Contacts and Locations

Locations

Site City State Country Postal Code
1 Medical University of Warsaw Warsaw Poland

Sponsors and Collaborators

  • AronPharma Sp. z o. o.
  • Medical University of Warsaw
  • Medical University of Gdańsk

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
AronPharma Sp. z o. o.
ClinicalTrials.gov Identifier:
NCT05843617
Other Study ID Numbers:
  • 01-AP-VC
First Posted:
May 6, 2023
Last Update Posted:
May 6, 2023
Last Verified:
Apr 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by AronPharma Sp. z o. o.
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 6, 2023